LLY vs SBFM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
SBFM exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company maintains a strong current ratio (4.17) and very low debt, these are overshadowed by negative revenue growth (-10.60%), consistent earnings misses, and a catastrophic long-term price collapse (-100% over 5 years). The single analyst's 'strong buy' recommendation and $5.60 target appear to be extreme outliers that contradict the deterministic data. The stock is trading at a deep discount to book value (P/B 0.22), but this is typical for distressed micro-cap biotech firms with failing growth trajectories.
Compare Another Pair
Related Comparisons
LLY vs SBFM: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Sunshine Biopharma, Inc. (SBFM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.